Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Other financing activities: 2018-2025

  • Collegium Pharmaceutical's Other financing activities rose 578.87% to $964,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year change of. This contributed to the annual value of -$16,000 for FY2015, which is N/A change from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Other financing activities stood at $964,000, which was up 125.23% from $428,000 recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Other financing activities registered a high of $5.9 million during Q2 2024, and its lowest value of $142,000 during Q3 2024.
  • In the last 2 years, Collegium Pharmaceutical's Other financing activities had a median value of $696,000 in 2025 and averaged $1.9 million.
  • Data for Collegium Pharmaceutical's Other financing activities shows a peak YoY increase of 578.87% (in 2025) and a maximum YoY decrease of 92.71% (in 2025) over the last 5 years.
  • Collegium Pharmaceutical's Other financing activities (Quarterly) stood at $142,000 in 2024, then soared by 578.87% to $964,000 in 2025.
  • Its last three reported values are $964,000 in Q3 2025, $428,000 for Q2 2025, and $142,000 during Q3 2024.